MIAMI, FL--(MARKET WIRE)--Sep 12, 2007 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News) ("DOR" or the "Company") announced today that its academic partner, the Fred Hutchinson Cancer Research Center (FHCRC), has received a $1 million grant from the National Institute of Health (NIH) to conduct preclinical studies of oral Beclomethasone Dipropionate (oral BDP, also the active ingredient in orBec®) for the treatment of gastrointestinal (GI) radiation injury.
